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Insulin resistance in skeletal muscle tissues and diabetes-related muscle weakness are serious pathophysiological problems of
increasing medical importance. In order to determine global changes in the protein complement of contractile tissues due to
diabetes mellitus, mass-spectrometry-based proteomics has been applied to the investigation of diabetic muscle. This review
summarizes the ﬁndings from recent proteomic surveys of muscle preparations from patients and established animal models
of type 2 diabetes. The potential impact of novel biomarkers of diabetes, such as metabolic enzymes and molecular chaperones,
is critically examined. Disease-speciﬁc signature molecules may be useful for increasing our understanding of the molecular and
cellular mechanisms of insulin resistance and possibly identify new therapeutic options that counteract diabetic abnormalities in
peripheral organ systems. Importantly, the biomedical establishment of biomarkers promises to accelerate the development of
improved diagnostic procedures for characterizing individual stages of diabetic disease progression, including the early detection
of prediabetic complications.
1.Introduction
The incidence of diabetes mellitus has reached epidemic
proportions and is one of the great biomedical challenges
of the 21st century [1]. Diabetes is classiﬁed as a group
of chronic metabolic disorders that are characterized by
elevated blood glucose levels due to the insuﬃcient pro-
duction of insulin and/or peripheral insulin resistance [2].
The strict division into type 1 and type 2 diabetes based
on an autoimmune etiology versus a primarily metabolic
pathology, respectively, has been challenged over the last few
years [3] and it has recently been suggested that a continuous
spectrum of diabetic disorders exist [4]. Classical type 2
diabetesisaheterogeneousclusterofdisorders,wherebyboth
lifestyle and genetic factors play a role in its pathogenesis
[2]. An abnormal expression pattern in a number of genes
and various proteins has been described to occur in type
2 diabetes [5–7]. Besides impaired pancreatic functioning,
peripheral insulin resistance in adipose tissue, the liver,
and muscle tissues are the pathophysiological hallmarks
o ft h i st y p eo fd i a b e t e s[ 8]. Serious medical problems
manifestthemselvessuchasdiabeticretinopathy[9],diabetic
uropathy [10], diabetic foot infection [11], and diabetic
nephropathy [12]. Glucotoxic and lipotoxic side eﬀects due
to chronic hyperglycemia and hyperlipidemia, respectively,
may result in abnormal cellular functions [8]. The impaired
uptake of glucose and deleterious accumulation of lipids
triggers the principle feature of type 2 diabetes, that is, the
progressive dysregulation of carbohydrate homeostasis [13].
With respect to muscle tissues, diabetes aﬀects primarily
cardiac cells [14] and the classiﬁcation of diabetic cardiomy-
opathy as a distinct clinical entity is currently under intense
discussion [15–17]. Heart failure in diabetic patients, inde-
pendent of coronary artery disease, appears to represent a
discrete primary etiology [18]. However, the skeletal muscu-
lature is also signiﬁcantly involved in diabetic complications,
that is, contractile weakness, ﬁbre-type changes, decreased
oxidative activity and peripheral insulin resistance [19].
Muscleisthemostimportantinsulin-dependentglucosesink
in the body [20], therefore, impaired hormonal signaling
has a deleterious eﬀect on glucose uptake. The detailed
biochemical characterization and proteomic establishment
of distinct shifts in metabolic and signaling pathways in
diabetic ﬁbres might provide mechanistic insights into the2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
underlying causes of (i) abnormal glucose metabolism [21]
and peripheral insulin resistance [22, 23], (ii) diabetes-
associated loss of skeletal muscle mass and contractile
strength [24, 25], which is especially prevalent in aged
patients [26, 27], (iii) muscle mitochondrial dysfunction
and the role of mitochondrial deﬁcits in overall disease
progression [28–30], and (iv) slow-to-fast muscle transitions
and reduced oxidative enzyme activity in muscle of type 2
diabetic subjects [31].
The fact that drastic lifestyle modiﬁcations, such as
an altered diet and increased physical activity [32], have
a profound inﬂuence on insulin resistance and the onset
of diabetic complications [33, 34] clearly demonstrates
the crucial role of skeletal muscle metabolism in diabetes
mellitus. Since a single bout of exercise triggers a substantial
increase in whole-body glucose disposal, mediated by the
translocation of the crucial glucose transporter GLUT4
to the surface membrane system in contracting skeletal
muscles [35], exercise training should play a key role in
the prevention and treatment of diabetes [36–38]. To better
understand these beneﬁcial eﬀects of physical activity, it will
be essential to increase our molecular understanding of how
exercise utilizes diﬀerent signaling mechanisms as compared
to hormonal regulation of glucose uptake. Genomic, pro-
teomic and metabolomic approaches are highly suited to the
conduction of such investigations and might determine the
best way to counteract diabetic complications in the skeletal
musculature.
2.Mass-Spectrometry-BasedSkeletal
MuscleProteomics
Modern proteomics attempts to identify, catalogue, and
characterize the entire protein constellation of speciﬁc cell
types,tissues,orbiologicalﬂuidsusinglarge-scaleseparation
methods, such as two-dimensional gel electrophoresis or
liquid chromatography, and high-throughput identiﬁcation
approaches focusing mostly on mass spectrometric tech-
niques [39]. Proteomic studies of plasma and cells with
mostly soluble components have revealed excellent coverage
of protein complements. However, the dynamic range of
protein expression in complex tissues and the large number
of hydrophobic protein species that are present in mem-
branous systems are major challenges for routine proteomic
surveys [40]. Immuno-depletion of abundant components,
equalization methods, or subcellular prefractionation can
be used to overcome some of the problems associated with
wide concentration ranges of proteins by reducing sample
complexity[41–43].Theanalysisofthemembraneproteome
can be achieved by employing detergent phase extraction
methods [44], on-membrane digestion protocols [45], or
ﬁlter-aided sample preparation [46] in order to include
hydrophobic elements in proteomic surveys.
However, aside from these technical problems, several
physiological, cell biological, and biochemical parameters
make the proteomic analysis of skeletal muscle an especially
diﬃcult task. In order to cover as many proteins as possible
in proteomic studies, the initial extraction process of tissue
samples is crucial. Since muscle ﬁbres are rigid structures
that are embedded in a complex system of connective tissue,
these biological properties make it an extremely tough
tissue to homogenize. Approximately half of the muscle
protein content consists of the contractile apparatus with
its various isoforms of myosin light chains, myosin heavy
chains, troponins, tropomyosins, and associated proteins.
Due to the high density of these proteins, a certain degree
of cross-contamination of protein spots cannot be avoided
during two-dimensional gel electrophoresis. In addition,
a large number of very high-molecular-mass proteins
exist in skeletal muscle ﬁbres, with some of them being
susceptible to proteolytic degradation [47]. The occurrence
of protein fragments has therefore to be taken into account
in proteomic analyses.
With respect to the under-representation of integral
proteins in most proteomic investigations of crude tissue
extracts, it is important to stress that skeletal muscles
exhibit a highly elaborate membrane system, consisting of
the sarcolemma, transverse tubules, triad junctions, the
sarcoplasmic reticulum, and abundant organelles such as
mitochondria. Since mature skeletal muscle tissues are
heterogeneous in composition, it has to be taken into
account that total extracts contain muscle ﬁbre proteins and
components derived from nerves, capillaries, basal lamina,
and satellite cells [48]. The musculature is physiologically
a highly adaptable system with the activity of the critical
nerve-muscle connection at the neuromuscular junction
dictating gene expression levels based on dynamic changes
in neuromuscular activity. Thus, ideally proteomic studies
have to take the protein complement of motor neuron
populations into account for comprehensive investigations
of the muscle proteome [49]. Predominantly fast-twitching
and slow-twitching ﬁbres, as well as its many subtypes
a n dh y b r i df o r m s ,d i ﬀer considerably in their proteomic
constellation and adaptive capacity [50–52]. An enormous
variety of myosin chain combinations can be found in
developing, maturing, and aging skeletal muscles [53]. In
this respect, mass-spectrometry-based proteomics is an ideal
tool to diﬀe r e n t i a t es u b t y p e so fm u s c l eﬁ b r e sw i t h i nac r u d e
extract based on the unequivocal identiﬁcation of myosin
light and heavy chain combinations.
The cellular and functional integrity of muscles depends
heavily on constant loading and proper activity levels. On
the one hand, chronic electrostimulation or physical training
triggers profound changes in the protein expression pattern
of muscles [54–57], and on the other hand, disuse leads
inevitably to muscular atrophy [58–60]. Proteomics can be
employed to catalogue and characterize subtle changes in
the abundance and/or isoform expression during muscle
alterations. Recent scientiﬁc achievements and technical
challenges for future proteomic studies have been critically
examined in several reviews [47, 48, 61–63]. See Figure 1 for
the proteomic workﬂow of analyzing diabetic muscle tissues
using a gel electrophoresis-based approach.
3.ProteomicProﬁlingofDiabetesMellitus
Overthelastfewyears,mass-spectrometry-basedproteomics
has been established as a crucial analytical tool forbiomarkerJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
Prediabetic or diabetic skeletal muscle specimens
Gel electrophoresis-based proteomic analysis of diabetic muscle
Novel biomarker signature of type 2 diabetes 
- Improved diagnosis of type 2 diabetes 
- Candidates for prediabetic diagnosis
- Analysis of progressive stages of diabetes
- Identiﬁcation of new therapeutic targets
- Molecular pathogenesis of insulin resistance
Contractile proteins   
Signaling proteins   Ion-handling proteins Stress proteins  
Sample preparation
Crude extracts Subcellular fractions Protein fractions
Protein extraction
Urea-soluble 
Protein separation
Two-dimensional gel electrophoretic separation of soluble  protein fraction
Analysis of altered protein expression patterns
Comparison of gel electrophoretically separated protein complements
of normal versus diabetic specimens
Nonﬂuorescent dyes-Difference in-gel electrophoresis-Fluorescent dyes 
Coomassie dye RuBPs dye Fluorescent CyDyes 
Mass spectrometric identiﬁcation of altered proteins
Validation of proteomic ﬁndings
Immunoblot analysis–Immunoﬂuorescence microscopy–Enzyme assays
Metabolic enzymes    Metabolic transporters 
Protein fraction
Figure 1: Proteomic proﬁling strategy to evaluate the eﬀect of type 2 diabetes on skeletal muscle tissues. Shown is a ﬂowchart of the
proteomic workﬂow to identify new protein factors involved in the molecular pathogenesis of insulin resistance, abnormal cellular signaling,
and contractile weakness in diabetic skeletal muscle tissues. Listed are the various analytical steps of mass-spectrometry-based proteomic
surveys of muscle samples, such as sample preparation, protein extraction, gel electrophoretic separation, densitometric scanning, mass
spectrometric identiﬁcation of novel biomarkers, and the independent validation of proteomic data by immunoblotting, enzyme assays, and
immunoﬂuorescence microscopy.
discovery in the heterogeneous pathology of diabetes [64–
67].Proteomicstudieshavefocusedondiabeticnephropathy
[68–70], diabetic peripheral neuropathy [71] and diabetic
retinopathy [72, 73], as well as glucotoxicity and abnormal
islet function [74–76]. Although skeletal muscle ﬁbres also
play a major role in type 2 diabetes, only a few proteomic
surveys have addressed the issue of diabetes-related changes
in muscle protein expression levels, as listed in Table 1.
The sections below critically examine the impact of recently
published proteomic studies of type 2 diabetic skeletal
muscle tissues [77–85].
3.1. Proteomic Proﬁling of Human Muscle in Type 2 Diabetes.
The occurrence of diabetes and cardiovascular disease has
reached epidemic rates and there is a clear association of
these disorders with obesity-related complications. Impaired
insulin-mediated glucose uptake in skeletal muscle ﬁbres
is related to high levels of circulating free fatty acids, an
increased intramyocellular lipid content, diminished mito-
chondrial functioning and an overall weakened metabolic
ﬂexibility [21]. Pathobiochemical pathways that mediate
chronic low-grade inﬂammation represent the most likely
molecular link between obesity, diabetes, and cardiac disease
[86]. To properly study the role of obesity and diabetes in
disturbing skeletal muscle metabolism and to evaluate the
association between these two pathologies, a comparative
proteomic survey would ideally determine global protein
expression diﬀerences between age- and gender-matched,
lean, nondiabetic subjects, and individuals that are classiﬁed
as obese and diabetic, obese and nondiabetic, and nonobese
and diabetic. Since the availability of large numbers of
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Table 1: List of major proteomic proﬁling studies of skeletal muscle tissues from prediabetic and diabetic patients or animal models of type
2 diabetes.
Proteomic study New potential biomarkers References
Proteomic analysis of human vastus lateralis muscle
from type 2 diabetic subjects
Select number of potential markers of diabetes; abnormal
phosphorylation of ATP synthase; elevated levels of stress proteins [77, 78]
Proteomic proﬁling of skeletal muscle biopsy material
from patients suﬀering from type 2 diabetes
Establishment of a large number of muscle-associated signature
molecules of type 2 diabetes; changed abundance in various
mitochondrial proteins; abnormal phosphorylation of ATP synthase
beta-subunit
[79–81]
Proteomic proﬁling of rectus abdominus tissue from
obese and morbidly obese women with potential
prediabetic side eﬀects
Increased levels of key glycolytic enzymes suggests an obesity-related
compensatory glycolytic shift in muscle metabolism [87]
Proteomic analysis of gastrocnemius muscle from the
nonobese Goto-Kakizaki rat model of type 2 diabetes
Changes in muscle proteins associated with the contractile apparatus,
the antioxidant defense system, detoxiﬁcation mechanisms, the
cellular stress response, glucose metabolism, fatty acid utilization,
nucleotide metabolism, and amino acid metabolism
[82, 83]
Subproteomic survey of the muscle
mitochondria-enriched fraction from the non-obese
Goto-Kakizaki rat model of type 2 diabetes
Diﬀerential expression of various mitochondrial marker proteins
agrees with the idea that mitochondrial dysregulation plays a role in
type 2 diabetes
[84]
Comparative proteomic study of
fenoﬁbrate-dependent protein expression in skeletal
muscle from type 2 diabetic OLETF rats
Increased levels of the functionally unknown muscle protein
C11orf59 in a fenoﬁbrate-dependent manner in diabetic rat muscle [85]
Proteomic analysis of obese and potentially
prediabetic animal models
Generally perturbed protein expression levels in obese muscles,
aﬀecting especially metabolic enzymes [88–92]
surveys is a challenge, so far only a few proteomic studies
have addressed this fundamental question using human
muscle specimens [77–81].
Two-dimensional gel electrophoresis in combination
with MALDI-ToF MS analysis identiﬁed a small num-
ber of potential muscle-associated biomarkers for type 2
diabetes [77, 78]. The proteomic comparison of muscle
samples from 10 diabetic patients versus 10 healthy gender-
and age-matched controls revealed 8 potential markers
of type 2 diabetes in the fasting state. This included
the β-subunit of ATP synthase, isoforms of myosin light
chain MLC2, creatine kinase, the α1(IV)-chain of collagen,
glucose-regulated protein GRP78, the molecular chaperone
Hsp90,andtheglycolyticenzymephosphoglucomutase[77].
Increased levels of the heat shock proteins Hsp90 and GRP78
indicated increased cellular stress in diabetic muscle tissue.
Elevated concentrations of phosphoglucomutase suggested
an increased glycolytic-to-oxidative ratio in diabetic skeletal
muscle during the fasting state. Altered levels of the enzy-
matic interconversion of glucose-1-phosphate and glucose-
6-phosphate possibly play a role in altered glycogen and glu-
cose metabolism in diabetes [77]. Importantly, the catalytic
β-subunit of ATP synthase was shown to exhibit abnormal
phosphorylation in insulin-resistant muscle [77, 79]. The
biochemical comparison of muscle samples from cohorts of
healthy lean controls versus obese individuals versus patients
aﬄictedwith diabetes showed that the β-subunit of ATP syn-
thase is phosphorylated at multiple sites and that abnormal
phosphorylationpatternsarepresentindiabeticmuscle[79].
The human ATPsyn-β molecule exhibits phosphorylation
sites at Thr213, Tyr230, Tyr269, Thr312, Tyr361, Tyr395, and
Thr475,wherebyThr213islocatedinthenucleotide-binding
region of this enzyme. In muscle samples from obese and
diabetic individuals, Thr213 and Tyr361 in the β-subunit
of ATP synthase showed increased basal phosphorylation
levels. In addition, various enzymes involved in oxidative
phosphorylation were decreased in diabetic specimens [79].
Thus, dysregulation of ATP synthesis probably triggers
perturbations in mitochondrial functions and may be a
contributing factor in type 2 diabetes.
Recently, a more comprehensive proteomic study of
diabetic muscle was carried out by one-dimensional gel
electrophoresis and HPLC-ESI-MS/MS analysis. Hwang et
al. [80] compared the protein constellation of small per-
cutaneous vastus lateralis muscle biopsies from lean, obese
and type 2 diabetic subjects. This proteomic approach
had previously been successfully applied to catalogue the
human skeletal muscle protein complement and lead to
the identiﬁcation of 954 proteins in normal human vastus
lateralis [93]. In the diabetic muscle study, of 1,218 proteins
assigned by mass spectrometric identiﬁcation, 400 protein
species were present in at least half of the 24 volunteers.
A signiﬁcant increase or decrease was established in 15
muscle proteins [80]. While the expression of mitochondrial
elements was shown to be lower in diabetic muscle, several
molecular chaperones appear to be higher in insulin-
resistant ﬁbres. Increased levels of the molecular chaperones
Hsp90, T-complex protein, and chaperonin, as well as
the enzyme protein disulﬁde isomerase, agree with the
idea of increased cellular stress in diabetic ﬁbres [80]. An
altered concentration of α-actinin and its binding-protein
myozenin and a speciﬁc isoform of myosin indicate changes
in skeletal muscle structure. Drastically decreased mitochon-
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reductase and cytochrome c oxidase, conﬁrming a perturbed
mitochondrial functioning in type 2 diabetes [80]. Reduced
expression levels of genes encoding mitochondrial enzymes
have previously been demonstrated by microarray studies
[94].Interestingly,theproteomicsurveyofrectusabdominus
muscle from obese and morbidly obese women strongly
suggests a compensatory glycolytic shift [87]. Increased
glycolytic activity might represent a metabolic rescue to
counteract mitochondrial dysfunction during progressive
obesity- or diabetes-related impairments in oxidative muscle
metabolism. The comparative proteomic analysis of mito-
chondria from insulin-sensitive versus insulin-resistant vas-
tuslateralismusclesuggestsanaltereddensityofkeyenzymes
involved in fat oxidation which might be an important
contributory aspect of lipid accumulation in diabetes [79].
3.2. Proteomic Proﬁling of Animal Models of Type 2 Diabetes.
Sinceabnormalskeletalmusclefunctioningisamajorfeature
of type 2 diabetes, it can be expected that distinct changes
occur in the muscle proteome during the development of
insulin resistance and diabetes. Established animal models
with key symptoms of diabetes are, therefore, an ideal
experimental tool to study global alterations in the abun-
dance, isoform expression pattern, and/or posttranslational
modiﬁcations of muscle proteins.
3.2.1. Animal Models of Type 2 Diabetes. It is clearly evident
from the large number of publications on animal model
research covering diabetes mellitus that studying laboratory
animals had a signiﬁcant impact on understanding diabetic
pathogenesis, testing novel drugs, and evaluating toxic side
eﬀects [95–99]. Inbred animal strains show genetically
considerably less interindividual diﬀerences than human
subjects. Hence, a lower number of experimental repeats
is capable of producing meaningful sets of analytical data.
Since diabetes is a disease of both genetics and lifestyle
that shows a complex pattern of symptoms aﬀecting various
tissue and organ systems [4], no one diabetes-related animal
m o d e li ss u ﬃcient to study all of the clinical aspects of the
metabolic symptoms seen in patients. Therefore, a major
research drive is to generate new diabetes models focusing
on the various aspects of this complex metabolic disorder,
such as neuropathy, retinopathy, uropathy, cardiovascular
problems, and insulin resistance in skeletal muscle, as well
as the overall impact of glucotoxicity on body homeostasis
[2]. Enormous progress has been made by studying models
oftype1diabetes,suchasstreptozotocin-induceddiabetesin
rats [100], as well as type 2 diabetes including the nonobese
Goto-Kakizaki rat [101] and the obese Zucker rat [102].
With the emergence of genomics and proteomics, the
search for novel genes and protein factors involved in the
pathophysiology of diabetes has been decisively improved.
The proteomic proﬁling of animal disease models is highly
suitable for the identiﬁcation of new biomarker signatures,
for the development of superior diagnostics, and for the
evaluationofnoveltreatmentoptionstocounteractdiabetes-
related side eﬀects in skeletal muscle tissues. As reviewed
by Resj¨ o et al. [103], studying animal models of diabetes
using proteomics has provided unparalleled mechanistic
insights into the development of insulin resistance and
has revealed new biomedical opportunities for diabetes
prevention strategies. However, it is crucial to keep in mind
that related animal species may diﬀer markedly with regard
to drug eﬀects, toxic side eﬀects, dietary exposures, and
diabetes development, strongly suggesting that studying a
single animal system is not suﬃcient to properly predict
human responses. Although laboratory animals diﬀer from
humans in many physiological and biochemical responses
which may aﬀect the degree of cellular pathogenesis, studies
of diabetic animals can be helpful to human diabetes
predictions and prevention.
As discussed in general by Doran et al. [104], a good
animal model of diabetes should (i) closely resemble the
etiologyofhumandiabetesinonset,progression,complexity,
and severity, (ii) develop all or most of the multifactorial
aspects usually observed in advanced stages of human dia-
betes,(iii)mimicthebasicmechanismsofhumanphysiology
and metabolism that are important for insulin resistance,
(iv) be suitable for genetic manipulations and cell-based
treatment strategies, and (vii) be large enough to yield
suﬃcient amounts of biological samples for extended bio-
chemical analyses or to facilitate physiological procedures.
Theinitialﬁndingsfromcomparativeanimalproteomicscan
be extremely useful for making an informed decision on the
design of large-scale clinical proteomics investigation [104].
In the future, genetically engineered animal models promise
to be extremely helpful for determining the pharmacological
eﬃcacy of novel diabetic drugs. Thus, animal model research
will be an important prerequisite for proper drug selection
prior to the establishment of large-scale clinical trials for the
treatment of diabetes.
3.2.2. Proteomic Proﬁling of Skeletal Muscle from Diabetic
Animal Models. Since mass-spectrometry-based proteomic
studies of potential changes in the skeletal muscle proteome
have mostly focused on the Goto-Kakizaki rat [82–84],
the suitability of this animal model of type 2 diabetes is
brieﬂy described. The general diabetic status of mature
Goto-Kakizaki rats is exempliﬁed by the fact that their
blood glucose levels are signiﬁcantly elevated, but that the
concentration of nonfasting plasma insulin is not aﬀected
[101, 105, 106]. With respect to skeletal muscle tissues of
the Goto-Kakizaki rat, numerous studies have clearly shown
diabetes-related abnormalities, including (i) an inhibition of
insulin receptor autophosphorylation [107], (ii) abnormal
functioning of insulin signaling intermediates [108, 109],
(iii) an altered subcellular localization and diminished
recruitment of the main glucose transporter GLUT4 [110],
(iv) cytoskeletal defects in the sarcolemmal dystrophin-
dystroglycan complex [111], (v) a signiﬁcantly reduced
percentage of oxidative ﬁbres [112], and (vi) abnormal mito-
chondrial functioning [113]. Hence, chronically impaired
insulin signaling and associated downstream alterations in
skeletal muscle tissues make adult Goto-Kakizaki rats a
suitable animal model of type 2 diabetes.
The proteomic proﬁling of crude muscle extracts
and subcelluar fractions from the Goto-Kakizaki rat has
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visualization of protein spots in two-dimensional gels, that
is, colloidal Coomassie Blue [82], ﬂuorescent RuBPs[82, 83],
and ﬂuorescent CyDyes for diﬀerence in-gel electrophoretic
analysis [83, 84]. The diﬀerent labeling techniques clearly
showed variations in their dynamic visualization range,
so proteomic ﬁndings from the 3 dyes used for densito-
metric scanning could be combined for a more complete
coverage of changes within the diabetic muscle proteome.
Colloidal Coomassie staining, routinely used for reliable
protein detection following gel electrophoresis [114, 115],
and ﬂuorescence diﬀerence in-gel electrophoresis, which
represents one of the most powerful biochemical tools for
the comparative analysis of protein complements [116–
118], resulted in the detection of 929 [82] and 1734 [83]
protein spots, respectively. The silver staining technique and
protein labeling with the ﬂuorescent RuBPs dye (ruthenium
bathophenanthroline disulfonate) [119] were employed as
independent visualization methods for the veriﬁcation of
key ﬁndings in altered protein expression patterns [82, 83].
The mass spectrometric identiﬁcation of distinct changes
in proteins revealed that the nonobese diabetic phenotype
exhibits a generally perturbed protein expression pattern.
Aﬀectedproteinspecieswereshowntobeassociatedwiththe
contractile apparatus, the antioxidant defense system, detox-
iﬁcation mechanisms, the cellular stress response, glucose
metabolism, fatty acid utilization, nucleotide metabolism,
and amino acid metabolism [82–84].
The gel electrophoresis-based proteomic survey of nor-
mal versus nonobese diabetic rats showed an altered expres-
sion proﬁle for muscle-associated proteins that are involved
in lipolytic catabolism, the citric acid cycle, oxidative
phosphorylation, glycolysis, nucleotide metabolism, car-
bon dioxide removal, oxygen transportation, amino acid
catabolism, and cellular detoxiﬁcation mechanisms [82].
Mass spectrometry identiﬁed the enzymes with the high-
est decrease as carbonic anhydrase CA3 and 3-hydroxy-
isobutyrate dehydrogenase. The CA3 isoform of carbonic
anhydrasemediatesthevitalconversionofCO2 intocarbonic
acid in skeletal muscle tissues. Hence, the CO2-removal
mechanism appears to be impaired in diabetic muscles.
The degradation of leucine, valine, and isoleucine involves
the activity of hydroxy-isobutyrate, whereby the resulting
carbon skeleton is utilized as a metabolic substrate for the
generation of energy. The reduction of this rate-limiting
enzyme suggests that the degradation pathway of amino
acids is diminished in diabetic ﬁbres.
The proteomic analysis of nonobese diabetic muscle
revealed a diﬀerential eﬀect on glycolytic enzymes. The
concentration of enolase appears to be decreased, while
aldolase and phosphoglucomutase showed elevated levels
in muscle preparations from the Goto-Kakizaki rat [82].
Increased expression of phosphoglucomutase in diabetic
rat muscle agrees with the above-discussed ﬁndings of an
elevated density of this key glycolytic enzyme in human
diabetic skeletal muscle [77]. Altered levels of glycolytic
e n z y m e sw i l lh a v eap r o f o u n de ﬀect on the metabolic ﬂux
in diabetic muscle. However, numerous glycolytic enzymes
were shown to be multifunctional, making it diﬃcult to
conclude that peripheral insulin resistance in muscle directly
aﬀects the expression of select members of the 10-enzyme
system of muscle glycolysis.
Interestingly, increased levels of adenylate kinase isoform
AK1 and monoglyceride lipase were shown to exist in dia-
betic gastrocnemius muscle from the Goto-Kakizaki rat [82].
Changesinadenylatekinasecouldbeinterpreted asdiabetes-
related alterations in nucleotide metabolism and agrees
with ﬁndings from the proteomic analysis of obese skeletal
muscle [87]. The metabolic enzyme monoglyceride lipase
catalyses a key step in the hydrolysis of stored triglycerides
[120] and its increased abundance in diabetes may represent
compensatory energy utilization by the lipolytic pathway in
glucose-starved, nonobese muscle ﬁbres. In the absence of
alternative signaling mechanisms, such as exercise-induced
glucose transport, insulin resistance clearly generates a lack
of glucose removal from the circulatory system. Decreased
g l u c o s eu p t a k eb ys k e l e t a lm u s c l et i s s u e st h e nt r i g g e r sa
metabolic knock-on eﬀect on other biochemical pathways
such as gluconeogenesis, triacylglycerol hydrolysis, fatty acid
oxidation, and ketone body formation [21]. Thus, the
dysregulation of metabolism in diabetic muscle ﬁbres is
a highly complex pathology and proteomics has provided
additional information of hitherto undetected changes in
protein factors that may play a contributory role in type 2
diabetes. In the long term, a more complete comprehension
of these complex metabolic alterations will improve our
understanding of the overall pathobiochemical processes
that lead to peripheral insulin resistance and diabetes-related
muscle weakness.
In addition to newly detected changes in metabolic
enzymes, the ﬂuorescence diﬀerence in-gel electrophoretic
analysis of diabetic muscle revealed signiﬁcantly increased
levels of the small stress proteins αB-crystallin and Hsp27
[83]. The apparent upregulation of molecular chaperones
indicates an enhanced cellular stress response in the diabetic
phenotype. In general, stress proteins protect muscle cells
during unfavorable conditions, such as extreme hyper-
thermia, ischemic damage, hypoxic insult, exercise-induced
ﬁbre damage, traumatic injury, and in disease-associated
muscle degeneration [121]. The family of small heat shock
proteins is characterized by a conserved carboxy-terminal
sequence, the alpha-crystallin domain [122]. Cytoprotective
proteins containing this 90-residue domain are speciﬁcally
induced during injury to contractile ﬁbres [123]. Muscle-
speciﬁc molecular chaperones counteract deleterious protein
aggregation and speciﬁcally modulate intermediate ﬁlament
assembly [124]. The elements of the diabetes-associated
increase in the cellular stress response might be useful can-
didates for the establishment of a comprehensive biomarker
signature of type 2 diabetes.
Since mitochondrial dysfunction in skeletal muscle has
been implicated in the progression of diabetic pathology
[28–30], it is of considerable interest to determine how
the mitochondrial proteome is altered in diabetic ﬁbres.
Mitochondria play a key role in cell cycle progression, cal-
cium signaling, intermediary metabolism, protein transport,
regulation of apoptosis, and energy generation via oxidative
phosphorylation [125]. Altered protein expression levels
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intrinsically involved in numerous development processes,
the natural decline in body systems during aging, and the
progression of many diﬀerent pathologies [126]. As reviewed
by Distler et al. [127], the mitochondrial proteome con-
tains approximately 1,500 individual protein species. This
relatively manageable number of proteins can be routinely
analysed by proteomic technologies, establishing subcellular
proteomics as a suitable analytical method to evaluate global
alterations in the mitochondrial protein complement. The
ﬂuorescence diﬀerence in-gel electrophoretic analysis of
isolated mitochondria from diabetic gastrocnemius mus-
cle showed changed concentration levels of a variety of
metabolic enzymes [84]. An altered expression of NADH
dehydrogenase, cytochrome b-c1 complex, isocitrate dehy-
drogenase,pyruvatedehydrogenase,andATPsynthasemight
trigger a diabetes-dependent impairment of mitochondrial
oxidative phosphorylation in Goto-Kakizaki rat muscle.
Thus, mitochondrial abnormalities appear to play a contrib-
utory role in the molecular pathogenesis of type 2 diabetes
and may be associated with the progressive development of
insulin resistance [128]. With respect to human diabetes, the
recent successful phosphoproteomic cataloguing of human
muscle mitochondria by Zhao et al. [129] has demonstrated
that it will be possible to study functional mitochondria
from human muscle by proteomics in the future. Such
mass-spectrometry-based studies promise to determine the
potential role of altered mitochondrial protein expression
levels and/or posttranslational modiﬁcations in human type
2 diabetes.
Besides proteomic surveys of skeletal muscles from
nonobese type 2 diabetic animal models, mass spectro-
metric methodology was also applied to the evaluation of
fenoﬁbrate-fed type 2 diabetic OLETF rats [85], type 1
diabetic BB-DP rats [130], streptozotocin-induced type 1
diabetic mice [88], and animal models of obesity with a
potential for prediabetic complications, such as C57BL/6
mice on a high-fat diet [89], interleukin receptor-knockout
mice on a high-fat diet [90], capsaicin-treated obese rats
[91], and obesity-prone OP rats on a high-fat diet [92].
The pharmacological substance fenoﬁbrate is an agonist
of the peroxisome proliferator-activated class of receptors,
which are involved in the regulation of carbohydrate and
lipid metabolism. A functionally unknown muscle protein
named C11orf59 was shown to be markedly increased in a
fenoﬁbrate-dependent manner in diabetic OLETF rats [85].
Obesity appears to have a profound inﬂuence on the skeletal
muscle proteome, triggering a disturbed expression pattern
in various metabolic enzymes [89–91]. Thus, the loss of
metabolichomeostasisprobablyunderliesobesity-associated
disorders, such as the prediabetic syndrome and type 2
diabetes.
The main ﬁndings of proteomic surveys of diabetic mus-
cle preparations are summarized in Figure 2. Although only
a limited number of studies have been published that used
high-resolution two-dimensional gel electrophoresis or liq-
uidchromatographyincombinationwithmassspectrometry
for the analysis of type 2 diabetes, a large number of changed
muscle proteins involved in various cellular functions have
already been identiﬁed. The future application of detailed
biochemical, physiological, and cell biological analyses will
be crucial to determine the general suitability of these new
potential biomarkers as reliable indicators of downstream
eﬀects of insulin resistance and disease progression. This
will not only be important for improving our biomedical
understanding of the molecular pathogenesis that leads to
diabetes mellitus but also be helpful for the improved design
of diagnostics and the identiﬁcation of novel therapeutic
targets. As recently outlined by Herder et al. [131], the
establishment of novel biomarkers for the prediction of
type 2 diabetes is crucial to the identiﬁcation of high-risk
individuals who could beneﬁt from targeted preventive mea-
sures. In this respect the, albeit limited, application of mass-
spectrometry-based proteomics has shown that this highly
specialized biochemical technology can make a valuable
contribution to the general ﬁeld of diabetes research.
4. Conclusion
Cardiovascular diseases, obesity-related disorders aﬀecting
multiple organ systems, the metabolic syndrome, and
diabetes mellitus aﬀect hundreds of millions of patients
worldwide. These epidemiological facts warrant detailed
biomedical studies into the molecular and cellular mecha-
nisms of these crippling diseases. It is hoped that a better
understanding of the molecular pathogenesis of common
human disorders will help in the identiﬁcation of novel ther-
apeutic targets. In the long term, this should translate into
the development of superior pharmacological approaches
and better clinical treatment options. The etiology of type
2 diabetes appears to be inﬂuenced by both genetic and envi-
ronmental factors, making it a great challenge to determine
the causative interplay of genetic susceptibilities, pathophys-
iological aspects, and external features. A change in lifestyle,
such as increased physical activity and improved nutritional
regimes, can reverse some of the diabetic symptoms such as
insulin resistance. Diabetes is clearly a heterogeneous group
ofdisordersandcancauseextremelyserioussideeﬀects,such
as cardiomyopathy, stroke, lower limb amputation, kidney
failure, blindness, and skeletal muscular weakness. In the
older population, type 2 diabetes can result in signiﬁcantly
decreased muscle strength and may thus contribute to the
development of physical disability in the elderly. Sarcopenia
of old age, the natural age-related decline in skeletal muscle
mass and strength, can be exacerbated by the negative
inﬂuence of the diabetic phenotype on muscle metabolism.
It is, therefore, of the uttermost urgency to devise novel
approaches to counteract diabetes-related muscle weakness
and abnormal hormone signaling in of the most crucial
insulin-dependent organs for glucose disposal. Over the
last few years, mass-spectrometry-based proteomics has
been applied to diabetes research as an unbiased analytical
tool for the global determination of abnormal protein
expressionpatternsindiabeticmuscletissues.Theproteomic
proﬁling of both biopsy samples from diabetic subjects
and muscle extracts from established animal models has
resulted in the identiﬁcation of a variety of new potential
markers of diabetes. The biomarker signature of muscle-
related changes due to diabetes includes components that are8 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
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Figure 2: Overview of changes in diabetic skeletal muscle as revealed by mass-spectrometry-based proteomics. Shown is a diagram of a
skeletal muscle ﬁbre outlining sarcolemmal proteins involved in insulin signaling and glucose uptake, as well as major cellular mechanisms
aﬀected in diabetic muscle tissues. Listed are established diabetes-related impairments of insulin receptor (IR) phosphorylation and
abnormal signaling and transporter recruitment involving IRS1, p85, p110, Akt, PI-3-kinase, and glucose transporter isoform GLUT4.
Proteomic proﬁling of muscle tissues from patients and established animal models of type 2 diabetes have revealed changes in components
downstream from these plasmalemmal signaling cascades, including proteins involved in mitochondrial metabolism, glycolysis, contractile
apparatus, detoxiﬁcation mechanisms, cellular stress response, glucose metabolism, fatty acid utilization, nucleotide metabolism, and amino
acid metabolism.
associated with the actomyosin apparatus, the cellular stress
response, glucose utilization, fatty acid oxidation, and other
metabolic pathways. Interestingly, a very recent proteomic
study of human diabetic muscle clearly supports the idea
of oxidative-to-glycolytic shifts in energy metabolism of
the diabetic phenotype [132]. In addition, Thingholm et
al. [133] have recently examined human myotubes from
type 2 diabetic subjects and identiﬁed adenosine deaminase
as a contributing factor in diabetes. The identiﬁcation
and characterization of disease stage-speciﬁc indicators is
especially crucial for the evaluation of the prediabetic phase.
Insulin resistance in skeletal muscle represents one of the
main features of diabetes-related dysregulation and probably
develops during a relatively early phase of the prediabetic
state. Although low levels of insulin resistance can probably
be partially compensated by increased hormonal secretion
via enhanced pancreatic beta-cell activity in early type 2
diabetes, at more advanced stages of the disease, beta-cell
failure occurs resulting in an insuﬃcient concentration of
circulating insulin to prevail over signaling defects in muscle
tissue sensitivity. Building on the ﬁndings of the initial
proteomic surveys conducted, as outlined in this review,
future mass-spectrometry-based investigations promise to
identify new protein factors that will be indispensable
for the improvement of diagnostic techniques that could
monitor diabetic progression, and the discovery of superior
therapeutic targets to eliminate peripheral insulin resistance
and diabetes-associated contractile weakness.
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